To prove that the upregulation of ADGRG1 in AML CD8+ T cells signifies tumor-reactive T cells, we isolated ADGRG1+CD8+ T cells and ADGRG1−CD8+ T cells from the BM samples of newly diagnosed AML patients with RUNX1::RUNX1T1 (Supplementary Table S8) and co-cultured them with the matched patient’s BM CD34+ leukemia blast cells (Fig. 6H, Supplementary Figure S7C). This evidence concerns the gene ADGRG1 and acute myeloid leukemia.